Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

326
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
326
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

425
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
425
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

554
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
554
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

618
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
618
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

720
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
720

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Targeting Inflammation in Obesity and the Cardiovascular-Kidney-Metabolic (CKM) Syndrome Spectrum: A Narrative Review.

Obesity facts·2026
Same author

Erythrocyte and Platelet Indices at Admission and Discharge Stratify Long-Term Cardiovascular Risk After Invasive Treatment of Myocardial Infarction.

Journal of clinical medicine·2026
Same author

Inflammatory Biomarkers and Their Associations with Arrhythmic Burden Following SGLT2-I Treatment in Chronic Heart Failure-A Subanalysis of the ERASe Trial.

Journal of clinical medicine·2026
Same author

Hostile Aortic Neck Anatomy Increases Risk of Intraoperative Type I Endoleak After Endovascular Aneurysm Repair: Analysis of the Vascular Quality Initiative.

The Journal of surgical research·2026
Same author

A Systematic Review of Literature to Assess the Role and Utilization of Palliative Care in Vascular Surgery Patients.

Annals of vascular surgery·2026
Same author

Editorial: Next-generation technologies and multidisciplinary integration for oral cancer diagnosis and treatment.

Frontiers in oral health·2026

相关实验视频

Updated: Jun 17, 2025

Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock
06:30

Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock

Published on: May 19, 2022

5.9K

贝塔阻塞剂与增加的死亡率有关,但在内血管腹腔大动脉修复 (EVAR) 后的再干预减少.

Raquel Vicario-Feliciano1, Ahsan Zil-E-Ali1, Faisal Aziz1

  • 1Division of Vascular Surgery, Heart and Vascular Institute, Pennsylvania State Milton S. Hershey Medical Center, Hershey, PA.

Annals of vascular surgery
|August 5, 2024
PubMed
概括
此摘要是机器生成的。

贝塔抑制剂 (BBs) 不会减少血管内大动脉动脉瘤修复 (EVAR) 后的重新干预. 在BBs的患者有较高的死亡风险和1年后移植闭塞再干预的风险.

更多相关视频

A New Murine Model of Endovascular Aortic Aneurysm Repair
08:51

A New Murine Model of Endovascular Aortic Aneurysm Repair

Published on: July 7, 2013

14.4K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

21.2K

相关实验视频

Last Updated: Jun 17, 2025

Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock
06:30

Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock

Published on: May 19, 2022

5.9K
A New Murine Model of Endovascular Aortic Aneurysm Repair
08:51

A New Murine Model of Endovascular Aortic Aneurysm Repair

Published on: July 7, 2013

14.4K
The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

21.2K

科学领域:

  • 血管外科 血管外科
  • 心血管研究研究心血管研究
  • 医疗干预 医疗干预

背景情况:

  • 血管内动脉瘤修复后 (EVAR) 的囊行为及其对长期存活的影响仍然不清楚.
  • 有限的多中心试验调查β阻塞剂 (BBs) 对EVAR囊行为的影响.
  • 以前的研究表明,BBs对一般或特定人群的腹腔大动脉动脉瘤囊回归没有好处.

研究的目的:

  • 为了评估β阻塞剂 (BBs) 和EVAR后囊行为之间的关联.
  • 评估BBs对EVAR后的再干预率和死亡率的影响.

主要方法:

  • 从血管质量倡议 (2003-2021) 中对接受EVAR患者的分析.
  • 基于在出院时使用BB的患者分层.
  • 主要结局包括死亡率和30天和1年后的重新干预,并分析了重新干预的原因.

主要成果:

  • 总共有50,411名患者被研究;57.3%的人使用BBs.
  • 在BB和非BB组之间的总体再干预没有显著差异 (P=0.061).
  • 接受BB治疗的患者对移植塞的再干预率较低 (11.77%与18.70%,P=0.002),但30天和1年死亡率较高 (P<0.001).
  • 在接受BB的患者中,观察到1年死亡率的风险增加了26% (HR: 1.26 [1.10-1.41],P<0.001).

结论:

  • 贝塔抑制剂 (BBs) 在EVAR后不会减少内血管再干预.
  • 在BBs上的患者在EVAR后表现出更高的死亡率.
  • 对动脉瘤行为的BBs理论上的好处没有得到这种大规模分析的支持.